$VINC
Vincerx Pharma, Inc.

2024 Q3 Form 10-Q Financial Statement

#000119312524197025 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.885M $3.612M
YoY Change 10.46% -4.62%
% of Gross Profit
Research & Development $3.908M $3.754M
YoY Change -42.53% -52.32%
% of Gross Profit
Depreciation & Amortization $13.00K $13.00K
YoY Change 30.0% 0.0%
% of Gross Profit
Operating Expenses $7.793M $7.366M
YoY Change -24.46% -36.83%
Operating Profit -$7.793M -$7.366M
YoY Change -24.46% -36.83%
Interest Expense $154.0K $157.0K
YoY Change -40.77% -24.88%
% of Operating Profit
Other Income/Expense, Net -$50.00K $5.558M
YoY Change -108.31% 991.94%
Pretax Income -$7.843M -$1.808M
YoY Change -19.27% -83.79%
Income Tax
% Of Pretax Income
Net Earnings -$7.843M -$1.808M
YoY Change -19.27% -83.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17 -$0.05
Diluted Earnings Per Share -$0.17 -$0.05
COMMON SHARES
Basic Shares Outstanding 29.67M 29.53M
Diluted Shares Outstanding 45.67K 38.34K

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.09M $16.32M
YoY Change -51.51% -40.35%
Cash & Equivalents $2.942M $7.923M
Short-Term Investments $7.144M $8.396M
Other Short-Term Assets $231.0K $334.0K
YoY Change -59.54% -85.87%
Inventory
Prepaid Expenses $283.0K $530.0K
Receivables
Other Receivables
Total Short-Term Assets $11.75M $18.28M
YoY Change -48.51% -42.53%
LONG-TERM ASSETS
Property, Plant & Equipment $85.00K $98.00K
YoY Change -37.96% -35.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $173.0K $122.0K
YoY Change -80.21% -80.45%
Total Long-Term Assets $3.199M $3.244M
YoY Change -7.49% -6.3%
TOTAL ASSETS
Total Short-Term Assets $11.75M $18.28M
Total Long-Term Assets $3.199M $3.244M
Total Assets $14.95M $21.53M
YoY Change -43.12% -38.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.963M $1.536M
YoY Change -35.89% -56.52%
Accrued Expenses $1.724M $2.428M
YoY Change -61.91% -43.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.424M $5.332M
YoY Change -38.68% -41.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K $50.00K
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $50.00K $50.00K
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.424M $5.332M
Total Long-Term Liabilities $50.00K $50.00K
Total Liabilities $5.839M $6.079M
YoY Change -44.58% -45.43%
SHAREHOLDERS EQUITY
Retained Earnings -$181.2M -$173.3M
YoY Change 15.74% 18.06%
Common Stock $3.000K $3.000K
YoY Change 50.0% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.108M $15.45M
YoY Change
Total Liabilities & Shareholders Equity $14.95M $21.53M
YoY Change -43.12% -38.97%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.843M -$1.808M
YoY Change -19.27% -83.79%
Depreciation, Depletion And Amortization $13.00K $13.00K
YoY Change 30.0% 0.0%
Cash From Operating Activities -$6.379M -$5.827M
YoY Change -3.99% -54.11%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.374M -$8.337M
YoY Change -90.88% -156.32%
Cash From Investing Activities $1.374M -$8.337M
YoY Change -90.88% -156.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 17.00M
YoY Change -100.0% 18181.72%
NET CHANGE
Cash From Operating Activities -6.379M -5.827M
Cash From Investing Activities 1.374M -8.337M
Cash From Financing Activities 0.000 17.00M
Net Change In Cash -5.005M 2.838M
YoY Change -159.5% 29.0%
FREE CASH FLOW
Cash From Operating Activities -$6.379M -$5.827M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39244
dei Entity Registrant Name
EntityRegistrantName
Vincerx Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3197402
dei Entity Address Address Line1
EntityAddressAddressLine1
260 Sheridan Avenue, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
800-6676
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VINC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29671903
us-gaap Fair Value Net Derivative Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List
FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#MarketableSecuritiesUnrealizedGainLoss
us-gaap Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration
GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7923000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12782000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
82000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
72000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
8396000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
530000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51000
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1018000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1044000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
334000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
784000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
18283000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
14733000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1693000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2201000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
98000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125000
CY2024Q2 us-gaap Grants Receivable Noncurrent
GrantsReceivableNoncurrent
1331000
CY2023Q4 us-gaap Grants Receivable Noncurrent
GrantsReceivableNoncurrent
1076000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82000
CY2024Q2 us-gaap Assets
Assets
21527000
CY2023Q4 us-gaap Assets
Assets
18217000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1536000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2497000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2428000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1755000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1236000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1162000
CY2024Q2 vinc Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
132000
CY2023Q4 vinc Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
191000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5332000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5605000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
697000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1340000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2024Q2 us-gaap Liabilities
Liabilities
6079000
CY2023Q4 us-gaap Liabilities
Liabilities
6995000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29671903
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29671903
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21407510
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21407510
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
188770000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170324000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173349000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159112000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
15448000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11222000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21527000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18217000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3612000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3811000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6534000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8308000
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3754000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8248000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8310000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
19159000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
7366000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
12059000
us-gaap Operating Expenses
OperatingExpenses
14844000
us-gaap Operating Expenses
OperatingExpenses
27467000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7366000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12059000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14844000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27467000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5263000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
118000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-59000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
157000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
327000
us-gaap Investment Income Interest
InvestmentIncomeInterest
256000
us-gaap Investment Income Interest
InvestmentIncomeInterest
793000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
138000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
300000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
292000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
574000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5558000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
509000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
607000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1267000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1808000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11550000
us-gaap Net Income Loss
NetIncomeLoss
-14237000
us-gaap Net Income Loss
NetIncomeLoss
-26200000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32000
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
32000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
63000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1844000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11516000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14221000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26105000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38339
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38339
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21274
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21274
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29869
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29869
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21231
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21231
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-622000
CY2024Q2 us-gaap Payments For Commissions
PaymentsForCommissions
657000
CY2024Q2 vinc Issuance Of Pre Funded Warrants And Common Stock From Public Offering
IssuanceOfPreFundedWarrantsAndCommonStockFromPublicOffering
14752000
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
239000
CY2024Q2 vinc Issuance Of Common Stock In Connection With At The Market Offering
IssuanceOfCommonStockInConnectionWithAtTheMarketOffering
2161000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
89000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
912000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31000
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1808000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
15448000
us-gaap Payments For Commissions
PaymentsForCommissions
657000
vinc Issuance Of Pre Funded Warrants And Common Stock From Public Offering
IssuanceOfPreFundedWarrantsAndCommonStockFromPublicOffering
14752000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
239000
vinc Issuance Of Common Stock In Connection With At The Market Offering
IssuanceOfCommonStockInConnectionWithAtTheMarketOffering
2161000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
94000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1440000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5000
us-gaap Net Income Loss
NetIncomeLoss
-14237000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
15448000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34466000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
93000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1093000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
32000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11550000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24136000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47668000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
96000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2477000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
63000
us-gaap Net Income Loss
NetIncomeLoss
-26200000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24136000
us-gaap Profit Loss
ProfitLoss
-14237000
us-gaap Profit Loss
ProfitLoss
-26200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1440000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2477000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
508000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
377000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-59000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001796129
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
64000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
510000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
29000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
937000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
295000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
543000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-961000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-532000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
673000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
365000
vinc Increase Decreasein Lease Liabilities
IncreaseDecreaseinLeaseLiabilities
-569000
vinc Increase Decreasein Lease Liabilities
IncreaseDecreaseinLeaseLiabilities
-412000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13567000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25789000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8337000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10588000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31277000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8337000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20689000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
94000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
96000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
14752000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
vinc Proceeds From At The Market Offering Net Of Transaction Costs
ProceedsFromAtTheMarketOfferingNetOfTransactionCosts
2161000
vinc Proceeds From At The Market Offering Net Of Transaction Costs
ProceedsFromAtTheMarketOfferingNetOfTransactionCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17007000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4849000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4984000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12854000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11733000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8005000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6749000
us-gaap Nature Of Operations
NatureOfOperations
<div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 1. NATURE OF BUSINESS </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 3), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> to develop, use, manufacture, commercialize, sublicense, and distribute (i) a bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule-drug conjugates, and (ii) a small molecule drug program, including a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">P-TEFb</div> inhibitor compound. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach. </div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16400000
us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
16900000
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the condensed consolidated financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Concentrations of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s future product candidates will require approvals from the FDA and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company. </div>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000000
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1000000
vinc Date Of Licence Agreement
DateOfLicenceAgreement
2020-10-07
CY2021Q1 vinc Licence Fee Paid
LicenceFeePaid
5000000
CY2022Q4 vinc Licence Fee Payable
LicenceFeePayable
1000000
CY2023Q4 vinc Licence Fee Payable
LicenceFeePayable
1000000
CY2024Q2 vinc Aggregate Milestone Payments Payable
AggregateMilestonePaymentsPayable
1000000000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
15115000
CY2020Q4 vinc Date Of Lease Agreement
DateOfLeaseAgreement
P5Y
CY2020Q4 vinc Date Of Lease Commencement
DateOfLeaseCommencement
2021-01-01
CY2020Q4 us-gaap Lease Cost
LeaseCost
1200000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1900000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1700000
CY2022Q3 vinc Lessee Operating Sub Lease Term Of Contract
LesseeOperatingSubLeaseTermOfContract
P18M
CY2022Q3 vinc Lessee Operating Sub Lease Rent Amount
LesseeOperatingSubLeaseRentAmount
50000000
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
154000000
us-gaap Sublease Income
SubleaseIncome
261000000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
299000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
299000
us-gaap Operating Lease Cost
OperatingLeaseCost
598000
us-gaap Operating Lease Cost
OperatingLeaseCost
598000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2024Q2 us-gaap Lease Cost
LeaseCost
299000
CY2023Q2 us-gaap Lease Cost
LeaseCost
299000
us-gaap Lease Cost
LeaseCost
598000
us-gaap Lease Cost
LeaseCost
598000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
330000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
317000
us-gaap Operating Lease Payments
OperatingLeasePayments
660000
us-gaap Operating Lease Payments
OperatingLeasePayments
634000
CY2024Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
658000
CY2024Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1372000
CY2024Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
28000
CY2024Q2 us-gaap Contractual Obligation
ContractualObligation
2058000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
125000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1933000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29671903
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21407510
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
50000000
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.167
CY2024Q2 vinc Commission And Offering Expenses To The Agent Involved In The Share Issue
CommissionAndOfferingExpensesToTheAgentInvolvedInTheShareIssue
200000
CY2024Q2 us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
47500000
CY2024Q2 vinc Commission And Offering Expenses To The Agent Involved In The Share Issue
CommissionAndOfferingExpensesToTheAgentInvolvedInTheShareIssue
700000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5219
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.74
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
134000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2657000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.19
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
100000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.1
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7770
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4388000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
9.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2024Q2 vinc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntrinsicValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.1
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
7.19
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.21
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.918
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.895
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
912000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1093000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1440000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2477000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1808000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11550000
us-gaap Net Income Loss
NetIncomeLoss
-14237000
us-gaap Net Income Loss
NetIncomeLoss
-26200000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38339
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38339
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21274
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21274
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29869
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29869
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21231
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21231
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33065000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33065000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8697000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8697000
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001193125-24-197025-index-headers.html Edgar Link pending
0001193125-24-197025-index.html Edgar Link pending
0001193125-24-197025.txt Edgar Link pending
0001193125-24-197025-xbrl.zip Edgar Link pending
d771678d10q.htm Edgar Link pending
d771678dex311.htm Edgar Link pending
d771678dex312.htm Edgar Link pending
d771678dex321.htm Edgar Link pending
d771678dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vinc-20240630.xsd Edgar Link pending
vinc-20240630_def.xml Edgar Link unprocessable
vinc-20240630_lab.xml Edgar Link unprocessable
vinc-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d771678d10q_htm.xml Edgar Link completed
vinc-20240630_cal.xml Edgar Link unprocessable